While AZD0156 monotherapy was effective in reducing intratumoral myoCAF accumulation (Supplementary Fig. S6I and S6J), the drug/vaccine combination significantly increased CD8 T-cell infiltration and reduced tumor volume compared with the single treatments (Fig. 6I–L and Supplementary Fig. S7A). The gene discussed is CD8A; the disease is neoplasm.